Advanced search
Publication Cover
Infection and Drug Resistance Volume 11, 2018 - Issue
Submit an article Journal homepage
115
Views
23
CrossRef citations to date
0
Altmetric
Original Research

Sputum bacteriology conversion and treatment out-come of patients with multidrug-resistant tuberculosis

Lingshuang Lv1 Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China
,
Tiecheng Li2 Department of Tuberculosis, the Fourth People’s Hospital of Lianyungang City, Lianyungang, China
,
Kun Xu1 Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China
,
Peiyi Shi1 Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China
,
Biyu He1 Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, China
,
Weimin Kong3 Department of Thoracic Surgery, the First People’s Hospital of Yancheng City, Yancheng, China
,
Jianming Wang1 Department of Epidemiology, Key Laboratory of Infectious Diseases, School of Public Health, Nanjing Medical University, Nanjing, ChinaCorrespondence[email protected]
&
Jian Sun3 Department of Thoracic Surgery, the First People’s Hospital of Yancheng City, Yancheng, ChinaCorrespondence[email protected]
 show all
Pages 147-154 | Published online: 23 Jan 2018

References

  • Dheda K, Barry CE 3rd, Maartens G. Tuberculosis. Lancet. 2016;387(10024):1211–1226.
  • Marais BJ. The global tuberculosis situation and the inexorable rise of drug-resistant disease. Adv Drug Deliv Rev. 2016;102:3–9.
  • World Health Organization. Global tuberculosis report 2015. 2016; Available from: http://www.who.int/tb/publications/2016/en/. Accessed Aug 8, 2017.
  • Zhang J, Gou H, Hu X, et al. Status of drug-resistant tuberculosis in China: a systematic review and meta-analysis. Am J Infect Control. 2016;44(6):671–676.
  • Shao Y, Yang D, Xu W, et al. Epidemiology of anti-tuberculosis drug resistance in a Chinese population: current situation and challenges ahead. BMC Public Health. 2011;11:110.
  • Pablos-Mendez A, Raviglione MC, Laszlo A, et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization – International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. N Engl J Med. 1998;338(23):1641–1649.
  • Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med. 2014;371(8):723–732.
  • World Health Organization. Treatment of tuberculosis: Guidelines for National Programmes. 2003. Available from: http://www.who.int/docstore/gtb/publications/ttgnp/. Accessed Aug 8, 2017.
  • Lu P, Liu Q, Martinez L, et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban China. Eur Respir J. 2017;49(3):1601558.
  • World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency update. 2008. Available at from: http://www.who.int/tb/challenges/mdr/programmatic_guidelines_for_mdrtb/en/. Accessed Aug 8, 2017.
  • [no authors listed]. Guidelines for surveillance of drug resistance in tuberculosis. WHO Geneva/IUATLD Paris. International Union against Tuberculosis and Lung Disease. Int J Tuberc Lung Dis. 1998;2(1):72–89.
  • Kurbatova EV, Cegielski JP, Lienhardt C, et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: a secondary analysis of data from two observational cohort studies. Lancet Respir Med. 2015;3(3):201–209.
  • Tupasi TE, Garfin AM, Kurbatova EV, et al. Factors associated with loss to follow-up during treatment for multidrug-resistant tuberculosis, the Philippines, 2012–2014. Emerg Infect Dis. 2016;22(3):491–502.
  • Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, Trebucq A. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19(5):517–524.
  • Bastos ML, Lan Z, Menzies D. An updated systematic review and meta-analysis for treatment of multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3):1600803.
  • Perrin FM, Lipman MC, McHugh TD, Gillespie SH. Biomarkers of treatment response in clinical trials of novel antituberculosis agents. Lancet Infect Dis. 2007;7(7):481–490.
  • Peloquin CA. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs. 2002;62(15):2169–2183.
  • Holtz TH, Sternberg M, Kammerer S, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: Predictors and relationship to treatment outcome multidrug-resistant TB sputum culture conversion. Ann Intern Med. 2006;144(9):650–659.
  • Phillips PP, Davies GR, Mitchison DA. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis. 2010;10(2):69–70.
  • Horne DJ, Royce SE, Gooze L, et al. Sputum monitoring during tuberculosis treatment for predicting outcome: systematic review and meta-analysis. Lancet Infect Dis. 2010;10(6):387–394.
  • Kurbatova E, Gammino VM, Bayona J, et al. Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2012;16(10):1335–1343.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.